← Arcus Biosciences, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0 | $1.4m |
$8.4m
+491.15%
|
$15.0m
+79.58%
|
$77.5m
+416.78%
|
$382.9m
+393.93%
|
$112.0m
-70.75%
|
$117.0m
+4.46%
|
$258.0m
+120.51%
|
$247.0m
-4.26%
|
$117.0m
-52.63%
|
|
| Net Interest Income | $212k | $359k | $5.3m | $4.0m | $1.4m | $397k |
$14.0m
+3426.45%
|
$39.0m
+178.57%
|
$48.0m
+23.08%
|
$33.0m
-31.25%
|
$26.0m
-21.21%
|
|
| Research and development (Includes $25, ($39) and ($110) payments to/(from) a related party) | $14.2m | $47.2m | $49.6m | $78.5m | $159.3m | $256.3m | $288.0m | $340.0m | $448.0m | $523.0m | $497.0m | |
| General and administrative (Includes $5, $2 and $— payments to a related party) | $3.9m | $7.6m | $13.6m | $25.2m | $42.4m | $72.3m | $104.0m | $117.0m | $120.0m | $110.0m | — | |
| Operating Expenses | $18.2m | $54.9m | $63.2m | $103.7m | $201.8m | $328.6m | $392.0m | $457.0m | $588.0m | $633.0m | $603.0m | |
| Loss from operations | ($18.2m) |
($53.4m)
-193.92%
|
($54.9m)
-2.65%
|
($88.7m)
-61.70%
|
($124.2m)
-40.05%
|
$54.2m
+143.67%
|
($280.0m)
-616.15%
|
($340.0m)
-21.43%
|
($330.0m)
+2.94%
|
($386.0m)
-16.97%
|
— | |
| Operating Income (Loss) | ($18.2m) |
($53.4m)
-193.92%
|
($54.9m)
-2.65%
|
($88.7m)
-61.70%
|
($124.2m)
-40.05%
|
$54.2m
+143.67%
|
($280.0m)
-616.15%
|
($340.0m)
-21.43%
|
($330.0m)
+2.94%
|
($386.0m)
-16.97%
|
($486.0m)
-25.91%
|
|
| Interest Expense, Debt | — | — | — | — | — | — | — | — | $2.0m | $9.0m | $11.0m | |
| Interest Income | $212k | $775k | $4.9m | $5.2m | $1.4m | $657k | $16.0m | $41.0m | $52.0m | $41.0m | $37.0m | |
| Net Non Operating Interest Income Expense | $212k | $359k | $5.3m | $4.0m | $1.4m | $397k | $14.0m | $39.0m | $48.0m | $33.0m | $26.0m | |
| Income (Loss) from Equity Method Investments | — | ($416k) | ($886k) | ($1.2m) | ($613k) | — | — | — | — | — | — | |
| Interest and other income, net | $212k | $775k | $4.9m | $5.2m | $1.4m | $657k | $16.0m | $41.0m | $52.0m | $41.0m | — | |
| Interest Expense (non-operating) | — | — | — | — | — | — | $2.0m | $2.0m | $4.0m | $8.0m | $11.0m | |
| Total non-operating income, net | $212k | $359k | $5.3m | $4.0m | $1.4m | $397k | $14.0m | $39.0m | $48.0m | $33.0m | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | $53.9m | ($267.0m) | ($301.0m) | ($283.0m) | ($353.0m) | ($460.0m) | |
| Loss before income taxes | — | — | — | ($84.7m) | ($122.9m) | $54.6m | ($266.0m) | ($301.0m) | ($282.0m) | ($353.0m) | — | |
| Pre-Tax Income | — | — | — | ($84.7m) | ($122.9m) | $54.6m | ($266.0m) | ($301.0m) | ($282.0m) | ($353.0m) | ($460.0m) | |
| Income tax expense | — | — | — | — | — | ($1.8m) | ($1.0m) | ($6.0m) | ($1.0m) | $0 | $0 | |
| Net loss | ($18.0m) | ($53.1m) | ($49.6m) | ($84.7m) | ($122.9m) | $52.8m | ($267.0m) | ($307.0m) | ($283.0m) | ($353.0m) | — | |
| Net Income From Continuing And Discontinued Operation | ($18.0m) | ($53.1m) | ($49.6m) | ($84.7m) | ($122.9m) | $52.8m | ($267.0m) | ($307.0m) | ($283.0m) | ($353.0m) | ($460.0m) | |
| Income (Loss) from Continuing Operations, Per Basic Share | — | — | — | — | — | $1 | ($4) | ($4) | — | — | — | |
| Income (Loss) from Continuing Operations, Per Diluted Share | — | — | — | — | — | $1 | ($4) | ($4) | — | — | — | |
| Earnings Per Share, Basic | — | — | — | — | — | $0.76 | ($3.71) | ($4.15) | ($3.14) | ($3.29) | ($3.94) | |
| Earnings Per Share, Diluted | — | — | — | — | — | $0.71 | ($3.71) | ($4.15) | ($3.14) | ($3.29) | ($3.94) | |
| Weighted Average Number of Shares Outstanding, Basic | — | 3.9m | 36.4m | 45.4m | — | 69.3m | 72.0m | 74.0m | 90.1m | 107.4m | 119.1m | |
| Basic Average Shares | — | 3.9m | 36.4m | 45.4m | — | 69.3m | $72.0m | $74.0m | $90.1m | $107.4m | $119.1m | |
| Diluted Average Shares | — | 3.9m | 36.4m | 45.4m | — | 69.3m | $72.0m | $74.0m | $90.1m | $107.4m | $119.1m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | 74.0m | 72.0m | 74.0m | 90.1m | 107.4m | 119.1m | |
| Additional Financial Items | ||||||||||||
| Impairment of long-lived assets (see Note 14, Leases) | — | — | — | — | — | — | $0 | $0 | $20.0m | $0 | — | |
| Diluted EPS | — | — | — | — | — | $0.76 | ($3.71) | ($4.15) | ($3.14) | ($3.29) | ($3.94) | |
| Diluted NI Availto Com Stockholders | ($18.0m) | ($53.1m) | ($49.6m) | ($84.7m) | ($122.9m) | $52.8m | ($267.0m) | ($307.0m) | ($283.0m) | ($353.0m) | ($460.0m) | |
| Impairment Of Capital Assets | — | — | — | — | — | — | $0 | $0 | $20.0m | $0 | $0 | |
| Normalized EBITDA | — | — | — | — | — | — | ($258.0m) | ($291.0m) | ($248.0m) | ($335.0m) | ($439.0m) | |
| Normalized Income | — | — | — | — | — | — | ($267.0m) | ($307.0m) | ($267.2m) | ($353.0m) | ($460.0m) | |
| Other Gand A | $3.9m | $7.6m | $13.6m | $25.2m | $42.4m | $72.3m | $104.0m | $117.0m | $120.0m | $110.0m | — | |
| Reconciled Depreciation | — | — | — | — | — | — | $6.0m | $8.0m | $10.0m | $10.0m | $10.0m | |
| Selling General And Administration | $3.9m | $7.6m | $13.6m | $25.2m | $42.4m | $72.3m | $104.0m | $117.0m | $120.0m | $110.0m | — | |
| Special Income Charges | — | — | — | — | — | — | $0 | $0 | ($20.0m) | $0 | $0 | |
| Tax Effect Of Unusual Items | — | — | — | — | — | — | $0 | $0 | ($4.2m) | $0 | $0 | |
| Tax Provision | — | — | — | — | — | — | $1.0m | $6.0m | $1.0m | $0 | $0 | |
| Tax Rate For Calcs | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Total Unusual Items | — | — | — | — | — | — | $0 | $0 | ($20.0m) | $0 | $0 | |
| Total Expenses | — | — | — | — | — | — | $392.0m | $457.0m | $568.0m | $633.0m | $603.0m |